Physician profile
Parth Shah
NPI 1215564752
$2,604.11
in general payments reported to CMS, 2019-2025
13 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $758 · 2024: $554 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502 · Travel and Lodging: $839 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.50 |
| Travel and Lodging | $839.37 |
| Education | $263.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,250.13 | 2023-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Ensite Precision |
| Heartflow, INC. | $188.63 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $173.11 | 2023-2024 | Lifevest |
| Boston Scientific Corporation | $154.85 | 2023 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $143.82 | 2023-2024 | Amvuttra, Onpattro |
| E.R. Squibb & Sons, L.L.C. | $135.07 | 2023-2025 | Camzyos, Eliquis |
| Irhythm Technologies, INC. | $123.54 | 2024 | Zio Monitor, Zio Xt Patch |
| Esperion Therapeutics, INC. | $118.24 | 2024 | Nexletol |
| Amgen INC. | $113.64 | 2023 | Repatha |
| Pfizer INC. | $73.40 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $54.08 | 2025 | |
| Bridgebio Pharma, INC. | $37.82 | 2025 | Attruby |
| Abiomed | $37.78 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parth Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.